Display options
Share it on

Yonsei Med J. 2005 Feb 28;46(1):119-24. doi: 10.3349/ymj.2005.46.1.119.

Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.

Yonsei medical journal

Seong-Hwan Moon, Kyoo-Ho Shin, Jin-Suck Suh, Woo-Ick Yang, Jae-Keong Noh, Soo-Bong Hahn


  1. Department of Orthopaedic Surgery, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.

PMID: 15744814 PMCID: PMC2823037 DOI: 10.3349/ymj.2005.46.1.119


Change in tumor volume after chemotherapy appears to have a prognostic significance for the outcome of osteosarcoma. A newly developed volume measurement method based on three-dimensional summation with a proved reproducibility was utilized to measure osteosarcoma tumor volume. This retrospective analysis included 38 patients with biopsy- proven, nonsurface, skeletal high-grade osteosarcoma. The treatment was started by using three cycles of preoperative chemotherapy with cisplastin (100 mg/m2) and adriamycin (30 mg/m2). The tumor volume was measured before and after preoperative chemotherapy using three-dimensional magnetic resonance image measurement. The percentage of tumor necrosis was assessed by pathologic exam. After three cycle of postoperative chemotherapy, the patients were followed up at regular interval. For the 23 good responder patients, the mean survival time was 73.2 months (95% confidence interval 61.9-84.5 months), and for the 15 poor responder patients, the mean survival time was 50.8 months (95% confidence interval 38.6-63.1 months) (p<0.05). For the 14 patients with increased tumor volume after chemotherapy, the mean survival time was 47.5 months (range: 36.3-58.6 months) and for the 24 patients with stable or decreased tumor volume, the mean survival time was 74.3 months (range: 63.79-84.88 months) (p<0.05). Among the various factors, histopathologic response and tumor volume change after chemotherapy predicted disease free survival (p<0.05). Change in the tumor volume that was measured with a reproducible method and the histopathologic response after chemotherapy were the important predictors of disease free survival for osteosarcoma patients.


  1. J Clin Oncol. 1992 Jan;10(1):5-15 - PubMed
  2. J Clin Oncol. 1990 Dec;8(12):1988-97 - PubMed
  3. Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3 - PubMed
  4. Invest Radiol. 1992 May;27(5):367-73 - PubMed
  5. Clin Radiol. 1994 Jan;49(1):19-23 - PubMed
  6. Clin Radiol. 1995 Jun;50(6):384-90 - PubMed
  7. J Clin Oncol. 1996 Mar;14(3):848-58 - PubMed
  8. Clin Orthop Relat Res. 1997 Dec;(345):206-14 - PubMed
  9. J Clin Oncol. 1998 Feb;16(2):658-63 - PubMed
  10. Clin Orthop Relat Res. 2000 Jul;(376):200-8 - PubMed
  11. Cancer. 1975 Dec;36(6):2179-91 - PubMed
  12. Cancer. 1976 Jan;37(1):1-11 - PubMed
  13. Arch Pathol Lab Med. 1977 Jan;101(1):14-8 - PubMed
  14. Mayo Clin Proc. 1978 Nov;53(11):695-700 - PubMed
  15. J Bone Joint Surg Am. 1980 Sep;62(6):1027-30 - PubMed
  16. Cancer. 1982 Mar 15;49(6):1221-30 - PubMed
  17. Clin Orthop Relat Res. 1982 Jul;(167):250-4 - PubMed
  18. N Engl J Med. 1985 Dec 26;313(26):1637-43 - PubMed
  19. AJR Am J Roentgenol. 1990 Apr;154(4):763-9 - PubMed
  20. Radiology. 1990 Jun;175(3):791-6 - PubMed
  21. Cancer. 1992 Feb 1;69(3):698-708 - PubMed


MeSH terms

Publication Types